Literature DB >> 10384882

Edg-2 in myelin-forming cells: isoforms, genomic mapping, and exclusion in Charcot-Marie-Tooth disease.

J Allard1, S Barron, S Trottier, P Cervera, C Daumas-Duport, E Leguern, A Brice, J C Schwartz, P Sokoloff.   

Abstract

Edg-2 is an heptahelical receptor whose spatio-temporal distribution during rat brain development is consistent with a role in the control of myelination. We have now identified two splice variants of Edg-2 mRNA in rat brain that encode two receptor isoforms differing by a stretch of 18 amino acids in the NH2-terminal extracellular tail of the receptor. Prenatally (i.e., before oligodendrocyte myelination), the two variants detected by selective in situ hybridization are equally abundant, vary in parallel, and remain restricted to proliferative zones in the brain. Postnatally, the long isoform becomes predominant in myelinating structures, where its abundance increases sharply during the period of myelination. In the adult human brain, only the long variant was detected, while in situ hybridization showed it selectively expressed in the white matter and in clusters of cells showing features of oligodendrocytes of the temporal cerebral cortex. Consequently, the human Edg-2 gene was studied to assess its possible contribution in inherited neuropathies. The coding sequence was found to be contained in three exons and to map to chromosome 9q31.3-32 by using radiation hybrid panel and Yeast-Artificial Chromosomes. Two intragenic bi-allelic polymorphisms and a rare mutation were identified. As a first application to molecular genetic studies, they were used to exclude the Edg-2 gene in six families with phenotype of demyelinating Charcot-Marie-Tooth disease of unknown origin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10384882     DOI: 10.1002/(sici)1098-1136(199904)26:2<176::aid-glia8>3.0.co;2-k

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  5 in total

1.  Lysophosphatidic acid can support the formation of membranous structures and an increase in MBP mRNA levels in differentiating oligodendrocytes.

Authors:  Luciana Nogaroli; Larra M Yuelling; Jameel Dennis; Karen Gorse; Shawn G Payne; Babette Fuss
Journal:  Neurochem Res       Date:  2008-07-02       Impact factor: 3.996

2.  Anatomical location of LPA1 activation and LPA phospholipid precursors in rodent and human brain.

Authors:  Estibaliz González de San Román; Iván Manuel; María Teresa Giralt; Jerold Chun; Guillermo Estivill-Torrús; Fernando Rodríguez de Fonseca; Luis Javier Santín; Isidro Ferrer; Rafael Rodríguez-Puertas
Journal:  J Neurochem       Date:  2015-04-27       Impact factor: 5.372

3.  Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2).

Authors:  James J A Contos; Isao Ishii; Nobuyuki Fukushima; Marcy A Kingsbury; Xiaoqin Ye; Shuji Kawamura; Joan Heller Brown; Jerold Chun
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

4.  LPA1 , LPA2 , LPA4 , and LPA6 receptor expression during mouse brain development.

Authors:  Olga Suckau; Isabel Gross; Sandra Schrötter; Fan Yang; Jiankai Luo; Andreas Wree; Jerold Chun; David Baska; Jan Baumgart; Kuniyuki Kano; Junken Aoki; Anja U Bräuer
Journal:  Dev Dyn       Date:  2019-03-27       Impact factor: 3.780

5.  Modulation of Neurolipid Signaling and Specific Lipid Species in the Triple Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Estibaliz González de San Román; Alberto Llorente-Ovejero; Jonatan Martínez-Gardeazabal; Marta Moreno-Rodríguez; Lydia Giménez-Llort; Iván Manuel; Rafael Rodríguez-Puertas
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.